Other Current Assets	3 Months Ended
Mar. 31, 2022
Other Current Assets
Other Current Assets	4. Other Current Assets As of March 31, 2022, other current assets included prepaid expenses of $1.4 million, comprised primarily of prepayments of $1.0 million made for the Company’s clinical trials for prexigebersen in AML, BP1001-A in solid tumors as well as BP1002 in separate clinical trials for lymphoma and AML. Additionally, the Company had prepaid manufacturing development expenses of $0.3 million and prepaid insurance of $0.1 million. As of December 31, 2021, other current assets included prepaid expenses of $1.8 million, comprised primarily of prepayments of $1.4 million made for the Company’s clinical trials for BP1002 in AML and lymphoma, prexigebersen in AML and BP1001-A in solid tumors as well as prepaid insurance of $0.3 million and other prepaid expenses of $0.1 million.

Other Current Assets

3 Months Ended

Mar. 31, 2022

4. Other Current Assets

As of March 31, 2022, other current assets included prepaid expenses of $1.4 million, comprised primarily of prepayments of $1.0 million made for the Company’s clinical trials for prexigebersen in AML, BP1001-A in solid tumors as well as BP1002 in separate clinical trials for lymphoma and AML. Additionally, the Company had prepaid manufacturing development expenses of $0.3 million and prepaid insurance of $0.1 million. As of December 31, 2021, other current assets included prepaid expenses of $1.8 million, comprised primarily of prepayments of $1.4 million made for the Company’s clinical trials for BP1002 in AML and lymphoma, prexigebersen in AML and BP1001-A in solid tumors as well as prepaid insurance of $0.3 million and other prepaid expenses of $0.1 million.